Skip to main content
Download PDF
- Main
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP
- Busca, Alessandro;
- Salmanton-García, Jon;
- Corradini, Paolo;
- Marchesi, Francesco;
- Cabirta, Alba;
- Di Blasi, Roberta;
- Dulery, Remy;
- Lamure, Sylvain;
- Farina, Francesca;
- Weinbergerová, Barbora;
- Batinić, Josip;
- Nordlander, Anna;
- López-García, Alberto;
- Drgoňa, Ľuboš;
- Espigado-Tocino, Ildefonso;
- Falces-Romero, Iker;
- García-Sanz, Ramón;
- García-Vidal, Carolina;
- Guidetti, Anna;
- Khanna, Nina;
- Kulasekararaj, Austin;
- Maertens, Johan;
- Hoenigl, Martin;
- Klimko, Nikolai;
- Koehler, Philipp;
- Pagliuca, Antonio;
- Passamonti, Francesco;
- Cornely, Oliver A;
- Pagano, Livio
- et al.
Published Web Location
https://doi.org/10.1182/bloodadvances.2021005616Abstract
The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.